This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Acquisition Remove Avalon Remove Blogging Remove Develop
article thumbnail

After Investing, GSK to Buy Out Celiac Drug Developer Sitari Pharma

Xconomy

SEPTEMBER 11, 2019

GlaxoSmithKline is acquiring a startup it helped launch in 2013 as part of an alliance with life sciences venture capital firm Avalon Ventures. Avalon said Tuesday that GSK (NYSE: GSK ) has agreed to buy the company, Sitari Pharmaceuticals, which has been developing a treatment for celiac disease.

Avalon 56
Avalon Invest Southern California Develop 56
article thumbnail

Takeda Bases PvP Biologics Buyout on Promising Early Celiac Drug Data

Xconomy

FEBRUARY 26, 2020

Takeda (NYSE: TAK ) acquired the company for an undisclosed amount up front, plus up to $330 million in payments based on development and regulatory milestones for PvP’s experimental celiac disease drug KUMA062 (now TAK-062). That day is here. The deal follows completion of a Phase 1 study evaluating the PvP drug.

San Diego 72
San Diego Study Develop Development 72
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 5,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024